clinical trials of COVID-19

As part of the U.S. government’s response to the COVID-19 pandemic, NIAID(National Institute of Allergy and Diseases) is conducting and supporting clinical research to prevent, treat and better understand the respiratory illness.these efforts are made possible by the generous contributions of clinical research volunteers and are complemented by additional clinical research studies across the globe.A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral drug remdesivir in adults hospitalized with COVID-19 began in February 2020 at sites throughout the United States and around the world and closed to enrollment on April 19 with 1,063 participants. The trial compared daily investigational treatment of remdesivir delivered intravenously to a placebo control. Remdesivir is an investigational broad-spectrum antiviral treatment developed by Gilead Sciences, Inc. Initial results from the study show that remdesivir accelerates recovery from COVID-19.

In May, NIAID began a randomized, controlled clinical trial to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19.

A NIAID-supported study called HVTN 405/HPTN 1901 will describe immune responses to SARS-CoV-2 among people with a history of recovering from infection with the virus. This study also aims to develop antibody assays that can be reliably used in clinical research to detect immune responses to natural SARS-CoV-2 infection and distinguish them from responses to experimental vaccines and monoclonal antibodies against the virus.

https://www.youtube.com/watch?v=244STv94YTM